Zentalis Pharmaceuticals, Inc. (ZNTL)
3.77
+0.06
(+1.62%)
USD |
NASDAQ |
Sep 02, 16:00
3.71
-0.06
(-1.59%)
After-Hours: 04:45
Zentalis Pharmaceuticals Research and Development Expense (Annual) : 107.30M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 107.30M |
| December 31, 2024 | 167.77M |
| December 31, 2023 | 189.59M |
| December 31, 2022 | 172.73M |
| Date | Value |
|---|---|
| December 31, 2021 | 166.80M |
| December 31, 2020 | 84.90M |
| December 31, 2019 | 38.39M |
| December 31, 2018 | 18.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ARS Pharmaceuticals, Inc. | 13.18M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |